HHS, Defense Department invest in manufacturing demonstration to produce 100 million COVID-19 investigational vaccine doses
The Department of Health and Human Services today announced that it will partner with the Department of Defense to fund the advanced development — including clinical trials and large-scale manufacturing — of a COVID-19 investigational vaccine from Sanofi and GlaxoSmithKline.
The investment is expected to yield 100 million fill-finished doses, meaning vaccine doses are packaged and ready to ship immediately if clinical trials are successful and the Food and Drug Administration authorizes its use.
Related News Articles
Headline
A series of free videos from Med Tac offers guidance on how essential workers and the public can stay safe during the COVID-19 public health emergency.…
Headline
The AHA, American Medical Association, American Society of Health-System Pharmacists, and United States Pharmacopeia last week convened a virtual summit to…
Headline
The National Institutes of Health today announced clinical trials to investigate the safety and efficacy of a synthetic antibody therapy in COVID-19 patients.…
Headline
The Centers for Medicare & Medicaid Services will allow health insurers to offer premium reductions for individuals with 2020 coverage in the individual…
Headline
The Department of Health and Human Services Friday released specifications for reporting certain COVID-19 laboratory data as required by the Coronavirus Aid,…
Headline
The U.S. District Court for the Southern District of New York yesterday ruled against the Department of Labor regarding its regulations related to certain…